Stocks Health care ABCL
NASDAQ · Health careAbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. brought in $67.9M of revenue over the twelve months to September 30, 2026, up 92.1% from a year earlier. It posted a net loss of $148.3M. In fiscal 2025 capital spending exceeded operating cash flow by $174.1M. At September 30, 2026 it held $163.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about AbCellera Biologics Inc.
- Net worth
- AbCellera Biologics Inc. has a market value (market cap) of $3.7B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $75.1M (+160.6% year on year), with a net loss of $146.4M. Over the 12 months to September 30, 2026: revenue $67.9M, net loss $148.3M.
- Cash flow
- In fiscal 2025 operations used $131.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- AbCellera Biologics Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What AbCellera Biologics Inc. does
AbCellera Biologics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABCL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $75.1M | -$146.4M | -$0.49 | -$174.1M |
| 2024 | $28.8M | -$162.9M | -$0.55 | -$187M |
| 2023 | $38M | -$146.4M | -$0.51 | -$120.8M |
| 2022 | $485.4M | $158.5M | $0.50 | $206.7M |
| 2021 | $375.2M | $153.5M | $0.48 | $186.1M |
| 2021 | $233.2M | $118.9M | $0.45 | $13M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ABCL ranks in Health care
Latest SEC filings
What AbCellera Biologics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 19% to $10.6M versus the same quarter last year; diluted EPS -$0.13 versus -$0.19.
- November 9, 2026
- August 13, 2026
- August 10, 2026
- August 7, 2026Other event 8-K
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 76% to $4.1M versus the same quarter last year; diluted EPS -$0.18 versus -$0.12.
- August 5, 2026
- July 29, 2026Other event 8-K
- July 6, 2026
- June 17, 2026Other event 8-K
Insider trades
What the people running AbCellera Biologics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1.1M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 24, 2026 | Hayden Michael RDirector | Boughtindirect | 53,613 | $570.4K |
| August 18, 2026 | Montalbano John S.Director | Bought | 10,000 | $110.3K |
| August 14, 2026 | Booth AndrewChief Financial Officer | Bought | 37,200 | $383.9K |
| August 12, 2026 | Hayden Michael RDirector | Boughtindirect | 46,387 | $481K |
| August 11, 2026 | Hayden Michael RDirector | Gave as a giftindirect | 50,000 | - |
| June 3, 2026 | Booth AndrewChief Financial Officer | Exercised options | 250,000 | $47.5K |
| May 14, 2026 | Montalbano John S.Director | Bought | 20,000 | $95.4K |
| February 27, 2026 | Thermopylae Holdings Ltd.10% owner | Bought | 38,000 | $130.7K |
Who owns ABCL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13G, passive with 3 related filers | 10.8% | May 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 151 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 33,012,138 | +2,736,200 |
| Capital World Investors | 13,588,349 | +227,253 |
| Two Sigma Investments, LP | 10,437,431 | -124,634 |
| TD Waterhouse Canada Inc. | 9,568,149 | +3,490 |
| Bank of America Corp | 6,141,539 | +3,141,603 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4,317,206 | -3,258,270 |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 0 |
| BlackRock, Inc. | 3,805,309 | -234,927 |
| Driehaus Capital Management LLC | 2,864,729 | -1,160,050 |
| Tudor Investment Corp ET AL | 2,063,191 | -210,298 |
| Marshall Wace, Llp | 1,902,191 | +1,542,508 |
| UBS Group AG | 1,870,633 | -2,338,419 |
| Morgan Stanley | 1,669,014 | -555,815 |
| Citadel Advisors LLC | 1,586,512 | +225,407 |
| National Bank of Canada | 1,233,014 | +1,231,621 |
| Arrowstreet Capital, Limited Partnership | 1,039,927 | new |
| Renaissance Technologies LLC | 990,929 | -519,700 |
| Counterpoint Mutual Funds LLC | 971,643 | new |
| State Street Corp | 731,362 | +1,149 |
| DNB Asset Management AS | 677,479 | new |
Insiders
4 insiders reported holding 58,241,294 shares in total, about $728M at the last price.
| Holder | Shares |
|---|---|
| Thermopylae Holdings Ltd.10% owner | 56,134,097 |
| Hayden Michael RDirector | 1,373,3971,373,397 held indirectly |
| Booth AndrewChief Financial Officer | 482,800 |
| Montalbano John S.Director | 251,000 |
Questions about ABCL
What does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. is a company in the Health care sector, listed on NASDAQ as ABCL. Its shares trade on NASDAQ under the ticker ABCL.
What is AbCellera Biologics Inc.'s net worth?
AbCellera Biologics Inc. has a market value (market cap) of $3.7B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AbCellera Biologics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $148.3M on revenue of $67.9M.
How much revenue does AbCellera Biologics Inc. make?
Over the twelve months to September 30, 2026 AbCellera Biologics Inc. reported revenue of $67.9M. That is 92.1% more than a year earlier.
When did AbCellera Biologics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is AbCellera Biologics Inc.'s next earnings report?
AbCellera Biologics Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ABCL with
Follow ABCL
Get an email when AbCellera Biologics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AbCellera Biologics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.